OR WAIT 15 SECS
Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.
Teva has invested $110 million in a new sterile plant in Hungary. The company hopes the plant will strengthen the company's role in Hungarian drug development.
Teva has invested $110 million in a new sterile plant in Gödöllő, Hungary. With 15,000 m2 of production area and modular building, as well as an annual production capacity of 160–200 million units of injection products in six production lines, Teva hopes the plant will strengthen the company’s role in Hungarian drug production.
At the opening ceremony, which took place on Oct. 2, 2012, Jeremy Levin, president and CEO of Teva, highlighted the company’s commitment to quality drug production and its Hungarian employees. "This plant is the symbol of the harmony between the most up-to-date technology and the people, the creativity and hard work of our human capital."
According to a press statement, Teva’s new plant is not only one of the biggest sterile pharmaceutical plants, but also one of the most flexible ones in the world. The large production potential and flexibility means that the company will be able to supply patients in more than 70 countries, mainly in the US, Europe, and Far East.
Teva has been operating in Hungary since 1993 and employs more than 3500 people.
Related Content:PharmTech News